Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer[1][2].
[1]. Jonathan Stephens, et al. Rare disease landscape: will the blockbuster model be replaced• Expert Opinion on Orphan Drugs. Volume 2, 2014 - Issue 8.
[2]. Zhang J, et al. Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications. Cells. 2022 Oct 25;11(21):3362.